birtamimab
heidelberg pharmaceuticals,prothena
['birtamimab', 'heidelberg', 'prothena']
dr morie gertz presenting birtamimab in mayo 2012 stage iv al amyloidosis- posthoc analysis of vital trial, which was terminated for futility analysis. #ash2022 affirm-al trial ongoing with this antifibril agent in newly diagnosed pts with al. 
Director, Amyloidosis Center @BU_Amyloidosis Hematologist and Oncologist @The_BMC